Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes

Abstract

Novel, culture-independent, molecular and metagenomic techniques have provided new insight into the complex interactions between the mammalian host and gut microbial species. It is increasingly evident that gut microbes may shape the host metabolic and immune network activity and ultimately influence the development of obesity and diabetes. We discuss the evidence connecting gut microflora to obesity and to type 1 and type 2 diabetes, and we present recent insights into potential mechanisms underlying this relationship: increased nutrient absorption from the diet, prolonged intestinal transit time, altered bile acid entero-hepatic cycle, increased cellular uptake of circulating triglycerides, enhanced de novo lipogenesis, reduced free fatty acid oxidation, altered tissue composition of biologically active polyunsaturated fatty acid, chronic low-grade inflammation triggered by the endotoxin toll-like receptor 4 axis, and altered intestinal barrier function.

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

“…Three RCTs assessed probiotics in NAFLD: the first, evaluating VSL3, was prematurely terminated for an increase in hepatic steatosis [103]; the others, assessing a mixture of Lactobacillus spp. plus either Bifidobacterium bifidum or Streptococcus thermophilus, found a significant improvement in MRS-assessed hepatic fat and aminotransferases, respectively [104,105].…”

Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review

“…158 The causes of early improvement of MetS after bariatric surgery are complex and relate to changes on the entero-insular axis mediated by gastrointestinal hormones called incretins. [160][161][162] The anatomical changes caused by the surgical procedures, particularly duodenal exclusion and overflow of nutrients to the distal small bowel, lead to release of incretins, especially glucagon-like peptide 1 (GLP-1) and gastrointestinal insulinotropic polypeptide (GIP). These increase the production and release of insulin, improve peripheral insulin sensitivity and favor an anorexic state.…”

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

“…Furthermore, environmental pollutants 34 and specific bacterial intestinal colonization 35 have recently been proposed as additional risk factors for obesity, β-cell dysfunction and T2DM development. Thus, reversal of overnutrition (contributing to weight loss), lessening of adipose tissue disturbances and protection/ healing of the β cells should be treatment priorities 5,31 .…”